Skip to main content
Premium Trial:

Request an Annual Quote

Structural GenomiX and OSI Pharmaceuticals in Research Collaboration

NEW YORK, Sept. 3 (GenomeWeb News) -- Structural GenomiX of San Diego and OSI Pharmaceuticals of Melville, NY, announced a research collaboration, the companies said today.


SGX will apply its SGX gene-to-structure platform to explore OSI drug targets to determine oncology drug candidates. SGX will generate co-crystal data to meter target interaction.


SGX will receive undisclosed upfront payments, research funding, and milestone payments, the company said.